Observational Studies Should Get Safe Harbor For Preregistering Protocols – Humana
Executive Summary
Payors could get more faith in real world data – and sponsors might get more protections for disseminating them – if ISPOR/ISPE task force recommendations are adopted by industry and US FDA.
You may also be interested in...
Real World Evidence Benefits, Limits Explored In US FDA Demonstrations
FDA's Jacqueline Corrigan-Curay lists three demonstrations now underway that are aimed at looking at different aspects of generating real world evidence and may inform the agency's evaluation of the data and methods.
Real World Evidence Benefits, Limits Explored In US FDA Demonstrations
FDA's Jacqueline Corrigan-Curay lists three demonstrations now underway that are aimed at looking at different aspects of generating real world evidence and may inform the agency's evaluation of the data and methods.
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.